Current Issue
Volumes and Issues
For Authors
Manuscript Guidelines
Review Process
Conflict of Interest
Copyright
About the Journal
Editorial Board
Aim and Scope
Policy and Ethical Guidelines
Promotion of the Journal
Print-Version Subscription
Publisher and Contact Information
Contact Information
Sign in
ORIGINAL ARTICLE
HYPERBARIC OXYGEN THERAPY COMBINED WITH STEROID TREATMENT FOR SUDDEN SENSORINEURAL HEARING LOSS: A PROSPECTIVE RANDOMIZED CLINICAL TRIAL
1
Department of Otorhinolaryngology, Hygeia Hospital, Greece
2
Department of Otorhinolaryngology, Konstantopouleio General Hospital of Nea Ionia-Patisia, Greece
3
1st Academic Department of Otolaryngology, Head and Neck Surgery, Hippokrateio General Hospital, Kapodistrian University of Athens, Greece
4
2nd Academic Department of Otolaryngology, Head and Neck Surgery, Attiko General Hospital, Kapodistrian University of Athens, Greece
5
Hyperbaric Medicine, Hyperbaric and Diving Medical Center of Athens, Greece
6
Otolaryngology Department, Virginia Commonwealth University Richmond, United States
A - Research concept and design; B - Collection and/or assembly of data; C - Data analysis and interpretation; D - Writing the article; E - Critical revision of the article; F - Final approval of article;
Publication date: 2022-03-28
Corresponding author
Anastasia Piniara
Department of Otorhinolaryngology, Hygeia Hospital, 4 Erythrou Stavrou Street, 15123, Marousi, Athens, Greece
Department of Otorhinolaryngology, Hygeia Hospital, 4 Erythrou Stavrou Street, 15123, Marousi, Athens, Greece
J Hear Sci 2022;12(1):9-20
KEYWORDS
combined therapycorticotherapyaudiogramhyperbaric oxygenidiopathic sudden sensorineural hearing lossintratympanic steroids
TOPICS
ABSTRACT
Introduction:
The aim of this prospective randomized clinical trial was to compare the therapeutic efficacy of steroid treatment (systemic and intratympanic) versus combined administration of steroids and hyperbaric oxygen therapy (HBOT) as initial treatment in cases of idiopathic sudden sensorineural hearing loss (ISSNHL).
Material and methods:
102 patients with up to a 10-day history of ISSNHL were randomized into two groups and followed prospectively. Group A (52 patients) received prednisolone intravenously followed by methylprednisolone orally and 3 courses of intratympanic injections with dexamethasone, whereas Group B (50 patients) were administered a combination of the aforementioned treatment together with 10 sessions of HBOT. The patients were followed-up with audiograms and pure-tone averages (PTAs) were measured. Hearing change was evaluated by comparing pre- and posttreatment PTAs.
Results:
The final mean hearing gain was 21.0 for Group A and 31.1 dB HL for Group B. The 10.1 dB HL difference in favor of Group B was statistically significant (p=0.004). However, when recovery was assessed in terms of Siegel’s criteria, no statistically significant difference could be demonstrated. Patients younger than 45 years old achieved better hearing outcomes, and treatment was more effective at low frequencies (0.25 and 0.5 kHz). Combined HBOT and steroid treatment seems to provide greater hearing benefit for patients with severe hearing loss (initial PTA >70 dB HL).
Conclusions:
Early application of HBOT combined with systemic and intratympanic steroid administration significantly improved hearing outcomes with an absolute gain in PTA audiometric threshold of 10.1 dB (95% CI 1.5–29.8, p=0.004). Therefore, adding HBOT along with steroids as initial treatment in ISSNHL is recommended. Younger patients with severe hearing loss can be expected to derive most benefit.
The aim of this prospective randomized clinical trial was to compare the therapeutic efficacy of steroid treatment (systemic and intratympanic) versus combined administration of steroids and hyperbaric oxygen therapy (HBOT) as initial treatment in cases of idiopathic sudden sensorineural hearing loss (ISSNHL).
Material and methods:
102 patients with up to a 10-day history of ISSNHL were randomized into two groups and followed prospectively. Group A (52 patients) received prednisolone intravenously followed by methylprednisolone orally and 3 courses of intratympanic injections with dexamethasone, whereas Group B (50 patients) were administered a combination of the aforementioned treatment together with 10 sessions of HBOT. The patients were followed-up with audiograms and pure-tone averages (PTAs) were measured. Hearing change was evaluated by comparing pre- and posttreatment PTAs.
Results:
The final mean hearing gain was 21.0 for Group A and 31.1 dB HL for Group B. The 10.1 dB HL difference in favor of Group B was statistically significant (p=0.004). However, when recovery was assessed in terms of Siegel’s criteria, no statistically significant difference could be demonstrated. Patients younger than 45 years old achieved better hearing outcomes, and treatment was more effective at low frequencies (0.25 and 0.5 kHz). Combined HBOT and steroid treatment seems to provide greater hearing benefit for patients with severe hearing loss (initial PTA >70 dB HL).
Conclusions:
Early application of HBOT combined with systemic and intratympanic steroid administration significantly improved hearing outcomes with an absolute gain in PTA audiometric threshold of 10.1 dB (95% CI 1.5–29.8, p=0.004). Therefore, adding HBOT along with steroids as initial treatment in ISSNHL is recommended. Younger patients with severe hearing loss can be expected to derive most benefit.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
